

Surgically Targeted Radiation Therapy (STaRT)



A head STaRT in
the fight against
brain tumors



PATIENT EDUCATION

TOUGH ON THE TUMOR.
EASIER ON YOU AND YOUR CAREGIVERS.

GammaTile Therapy can eliminate the need for traditional radiation treatments, so you can focus on what matters most—healing.



The innovative design of the GammaTile keeps the radiation source from directly contacting the brain tissue while it delivers treatment to tumor cells.



GAMMATILE THERAPY | STaRT
RIGHT TREATMENT.
RIGHT TIME.
RIGHT PLACE.

- Your neurosurgeon places GammaTile(s) precisely where and when treatment will help the most—at the tumor site immediately after tumor removal.
- Radiation is focused right where it is needed—where the tumor is most likely to recur.
- GammaTile Therapy is designed to protect healthy tissue, minimizing radiation side effects, including hair loss.¹
- Radiation therapy occurs as you go about your daily life.



Ask your physician if GammaTile Therapy might be right for you.

TOUGH ON THE TUMOR.
EASIER ON YOU AND YOUR CAREGIVERS.

GammaTile Therapy can eliminate the need for traditional radiation treatments, so you can focus on what matters most—healing.



The innovative design of the GammaTile keeps the radiation source from directly contacting the brain tissue while it delivers treatment to tumor cells.




GAMMATILE THERAPY CLINICAL OUTCOMES.


Improved local tumor control in patients with recurrent meningiomas and recurrent brain metastases

For patients with recurrent meningiomas and recurrent brain metastases, the use of GammaTile Therapy demonstrated a significant delay in treatment site recurrence compared to their previous treatments.

MENINGIOMA PATIENTS RECURRENCE FREE AT 2 YEARS²



BRAIN METASTASES PATIENTS RECURRENCE FREE AT 1 YEAR³



Potential to extend overall survival in patients with recurrent glioblastoma

GammaTile Therapy demonstrates a potential for improved overall survival when comparing the effectiveness of surgery plus GammaTile Therapy to other treatment modalities across different clinical studies in patients with recurrent glioblastoma (GBM).

RECURRENT GBM PATIENTS MEDIAN OVERALL SURVIVAL^{4,5}



REFERENCES


1. Brachman D, Youssef E, Dardis C, et al. Surgically targeted radiation therapy: Safety profile of collagen tile brachytherapy in 79 recurrent, previously irradiated intracranial neoplasms on a prospective clinical trial. *Brachytherapy*. 2019;18(3):S35-S36.
2. Rogers L, Nakaji P, Youssef E, et al. Resection and surgically targeted radiation therapy for initial salvage treatment of aggressive meningioma: results from a prospective trial. Presented at: CNS 2020 Virtual Conference; September 30, 2020.
3. Brachman D, Nakaji P, Smith K, et al. A prospective trial of resection and surgically targeted radiation therapy for initial or salvage treatment of aggressive meningioma. Presented at: SNO 2020 Virtual Conference on Brain Metastases; August 14, 2020.
4. Data on file, GT Medical Technologies, Inc.
5. Tsien C, Pugh S, Dicker AP, et al. Randomized phase II trial of re-irradiation and concurrent bevacizumab versus bevacizumab alone as treatment for recurrent glioblastoma (NRG Oncology/RTOG 1205): initial outcomes and RT plan quality report. *International Journal of Radiation Oncology, Biology, Physics*. 2019;105(1):S78.

**TOP BRAIN TUMOR SPECIALISTS
CALL IT A GAME-CHANGER.
PATIENTS CALL IT A LIFE-CHANGER.**

The latest advancement in brain tumor treatment, GammaTile Therapy is FDA cleared for newly diagnosed malignant brain tumors and recurrent brain tumors, including glioblastomas, meningiomas, and metastatic brain tumors. Find a GammaTile Therapy center near you at gammatile.com.

**TREATMENT
CONSIDERATIONS.**

GammaTile Therapy is intended to deliver radiation therapy in patients with newly diagnosed malignant brain tumors and recurrent brain tumors. The potential for, and symptoms of, adverse events related to radiation exposure vary depending on the radiosensitivity of the exposed tissue, the amount of radiation delivered, and the placement of GammaTile(s). GammaTile Therapy should not be used for patients with known history of hypersensitivity to bovine-derived materials.



**IMPROVING THE LIVES
OF PATIENTS WITH BRAIN TUMORS**

©2020 GT Medical Technologies, Inc. | All rights reserved
GammaTile is a registered trademark of GT Medical Technologies, Inc.
MKT-007-1

gammatile.com | 1.833.662.0044